Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms

1989 • 1,111 citations

Taxol: A Novel Investigational Antimicrotubule Agent

1990 • 1,084 citations

THE IMPACT OF NATIONAL CANCER ACT

1991 • 809 citations

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1993 • 275 citations

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

1993 • 244 citations

Comprehensive Criteria for Assessing Therapy-Induced Toxicity

1990 • 234 citations

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1994 • 221 citations

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

1994 • 136 citations

TAXOL: A UNIQUE ANTIEOPLASTIC AGENT WITH SIGNIFICANT ACTIVITY IN ADVANCED OVARION EPITHELIAL NEOPLASM

1996 • 61 citations

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

1993 • 47 citations

Randomized Trial of Two Doses of Taxol in Metastatic Breast Cancer: An Interim Analysis

1994 • 43 citations

Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.

1993 • 17 citations